Moderna, Inc Shares Continue to Rise After Possible Vaccine Announcement

Published on: 26 Feb, 2020

Moderna, Inc., (NASDAQ: MRNA) shares continue to rise as the Coronavirus continues to spread globally. Shares of the Company jumped another 20% Wednesday and have crossed the $28 a share mark.

Moderna is a a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients. Earlier this week the Company announced that it has released the first batch of mRNA-1273, the Company’s vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) to be used in the planned Phase 1 study in the U.S.

mRNA-1273 is an mRNA vaccine against the novel coronavirus encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC). Manufacture of this batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

"I want to thank the entire Moderna team for their extraordinary effort in responding to this global health emergency with record speed. The collaboration across Moderna, with NIAID, and with CEPI has allowed us to deliver a clinical batch in 42 days from sequence identification," said Juan Andres, Chief Technical Operations and Quality Officer at Moderna. "This would not have been possible without our Norwood manufacturing site, which uses leading-edge technology to enable flexible operations and ensure high quality standards are met for clinical-grade material."

The Company’s manufacturing plant in Norwood, MA manufactures Moderna’s portfolio of mRNA development candidates, including vaccines and therapeutics. To date, the Company has produced and released more than 100 batches from its Norwood site for human clinical trials. mRNA-1273 is part of the Company’s core prophylactic vaccines modality, which has had six positive Phase 1 clinical readouts across six different vaccines over the past four years.


  • 3703Views
  • 6Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Bryan Shin



Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Related Posts

07 Jun, 2017 4055
20 Jun, 2017 3162
22 Jun, 2017 3311
28 Jun, 2017 3134



Feb 28, 2020 at 02 24 pm

Здравствуйте друзья!
Наша фирма сдает уютные домики в гурзуфе



Feb 28, 2020 at 02 25 pm

Привет товарищи[url=]![/url]
Наша контора сдает уютные домики в гурзуфе



Feb 28, 2020 at 02 27 pm

Здравствуйте товарищи[url=]![/url]
Наша организация сдает уютные домики в гурзуфе



Feb 28, 2020 at 02 28 pm

Приветствую Вас дамы и господа[url=]![/url]
Наша контора сдает уютные домики в гурзуфе



Jul 28, 2020 at 06 25 am

[url=]Amoxicillin No Prescription[/url] Amoxicillin Online



Jul 28, 2020 at 06 49 am

[url=]Amoxicillin[/url] Amoxicillin Online